Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer

Reuters12-04

<a href="https://laohu8.com/S/DRTS">Alpha Tau Medical</a> Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer

Alpha Tau Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT® alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596502-en) on December 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588887176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588887176","market":"us","top_or_hot":-1,"title":"Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT® alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596502-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DRTS\">Alpha Tau Medical</a> Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DRTSW\">Alpha Tau</a> Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT® alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596502-en) on December 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2Dm847:1","article_id":"2588887176","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588887176","pubTimestamp":1764856813,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alpha Tau Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology  Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","DRTS":"Alpha Tau Medical","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4082":"医疗保健设备","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Alpha Tau Medical启动Alpha DaRT治疗胰腺癌的美国临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"DRTS":0.9},"content_text":"Alpha Tau Medical Launches U.S. Clinical Trial of Alpha DaRT for Pancreatic Cancer\n    \n\nAlpha Tau Medical Ltd. has announced the initiation of a multi-center clinical trial in the United States to evaluate its Alpha DaRT® alpha-radiation cancer therapy for patients with newly diagnosed pancreatic cancer. The first patient was treated in September 2025, and the trial is expected to enroll up to 30 participants, with patient recruitment anticipated to be completed by the end of the first quarter of 2026. Additionally, two abstracts related to this research-focused on the feasibility, safety, efficacy, and immune response to Alpha DaRT in advanced pancreatic cancer-have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, scheduled for January 8-10, 2026. Results from a completed pilot trial in Montreal, Canada, will be presented at this event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596502-en) on December 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588887176","isCrawlerRequest":true}